{
  "id": 18695575,
  "title": "Medifast director Parsa Kiai buys $8,609 in company stock",
  "url": "https://urgent.news/2026/11/07/medifast-director-parsa-kiai-buys-8-609-in-company-stock",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-07T10:15:58.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/insider-trading-news/medifast-director-parsa-kiai-buys-8609-in-company-stock-93CH-5009804"
  },
  "original_language": "en",
  "account": "Parsa Kiai, a director of Medifast Inc. (NASDAQ: MED), recently purchased 661 shares of the company's common stock for a total of $8,609 on November 4, 2026. The shares were bought at an average price of $13.0255 per share, with prices ranging from $12.87 to $13.15 for each individual share. This acquisition increased Kiai's indirect holding of Medifast common stock to 21,089 shares. The current stock price is near $12.81, and the company has a relatively small market cap of $132 million. According to InvestingPro analysis, Medifast appears undervalued at present, despite facing profitability challenges with negative earnings of $3.69 per share over the past year. The company boasts strong gross profit margins of 69%. InvestingPro also provides 5 additional exclusive tips for MED investors and a comprehensive Pro Research Report on this and 1,400+ other US equities.\n\nKiai, as the Managing Member of Steamboat Capital Partners GP, LLC, may have a pecuniary interest in these shares, though he disclaims beneficial ownership except for his financial interest. Meanwhile, Medifast reported its Q3 2026 financial results, which surpassed Wall Street expectations. The company posted an adjusted earnings loss of $0.19 per share, significantly better than the projected $0.62 loss per share. Revenue for the quarter was $72.05 million, exceeding the estimated $67.7 million. These positive results suggest that Medifast's turnaround efforts are gaining momentum. Although specific upgrades or downgrades were not mentioned in the provided context, analysts have taken note of the company's performance. Investors should consider these developments as Medifast demonstrates the ability to outperform market expectations.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}